DIA Biosimilars 2013

Ironwood Pharmaceuticals

Almirall’s Constella approved in Europe for IBS-C

Wednesday, November 28, 2012 12:20 PM

The European Commission has granted marketing authorization to Almirall’s Constella (linaclotide 290mcg) for the symptomatic treatment of moderate to severe Irritable Bowel Syndrome with Constipation (IBS-C) in adults . This approval follows the positive recommendation received from the European Committee for Medicinal Products for Human Use (CHMP) in September.

More... »

Cenduit: Now with Patient Reminders

AstraZeneca, Ironwood announce linaclotide collaboration for China

Friday, October 26, 2012 02:20 PM

AstraZeneca, a global biopharmaceutical company, and Ironwood Pharmaceuticals, a Cambridge, Mass.-based entrepreneurial pharmaceutical company, have signed an agreement to co-develop and co-commercialize Ironwood’s linaclotide in China.

More... »

CRF Health – eCOA Forum

Depomed receives $1 million milestone payment from Ironwood

Friday, May 11, 2012 12:58 PM

Speciality pharmaceutical company Depomed of Menlo Park, Calif., has received a $1 million milestone payment from Ironwood Pharmaceuticals of Cambridge, Mass., following the development and delivery of a prototype formulation of an Ironwood development candidate.

More... »

CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs